These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34071012)

  • 21. Targeting the tumor microenvironment to improve clinical outcomes in triple negative breast cancer patients and bridge the current disparity gap.
    Alharbi M; Roy AM; Krishnan J; Kalinski P; Yao S; Gandhi S
    Front Immunol; 2024; 15():1428118. PubMed ID: 39072334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
    Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
    Front Immunol; 2022; 13():859581. PubMed ID: 35795662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High
    Nelson ED; Benesch MG; Wu R; Ishikawa T; Takabe K
    Am J Cancer Res; 2024; 14(1):227-242. PubMed ID: 38323277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
    Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
    Wang G; Romero Y; Thevarajan I; Zolkiewska A
    Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.
    Yang A; Wu M; Ni M; Zhang L; Li M; Wei P; Yang Y; Xiao W; An X
    Breast Cancer; 2022 May; 29(3):468-477. PubMed ID: 35061208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
    Yang X; Tang W; He Y; An H; Wang J
    Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer.
    Kok VC; Wang CCN; Liao SH; Chen DL
    Breast Cancer (Dove Med Press); 2022; 14():85-99. PubMed ID: 35437353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.
    Wu R; Oshi M; Asaoka M; Huyser MR; Tokumaru Y; Yamada A; Yan L; Endo I; Ishikawa T; Takabe K
    Am J Cancer Res; 2022; 12(2):744-762. PubMed ID: 35261799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.
    Oshi M; Sarkar J; Wu R; Tokumaru Y; Yan L; Nakagawa K; Ishibe A; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2022; 12(2):490-503. PubMed ID: 35261782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
    Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
    Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
    Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a CD8
    Dai YW; Wang WM; Zhou X
    Heliyon; 2023 Sep; 9(9):e19798. PubMed ID: 37810147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
    Shen X; Zhong J; He J; Han J; Chen N
    Front Immunol; 2022; 13():978092. PubMed ID: 36105819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Streptococcus virulence protein PepO triggers anti-tumor immune responses by reprograming tumor-associated macrophages in a mouse triple negative breast cancer model.
    Liu B; Huang J; Xiao J; Xu W; Zhang H; Yuan Y; Yin Y; Zhang X
    Cell Biosci; 2023 Nov; 13(1):198. PubMed ID: 37925462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.